Clinical Trial: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07211633) titled 'A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)' on Oct. 01.

Brief Summary: The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.

Study Start Date: July 09

Study Type: INTERVENTIONAL

Condition: Relapsing Multiple Sclerosis

Intervention: BIOLOGICAL: Ublituximab

Administered as an IV infusion.

BIOLOGICAL: Ublituximab

Administered as an SC injection.

Recruitment St...